Immunovaccine Inc. (TSX-V: IMV) is a clinical stage vaccine development company focused on advancing its patented DepoVax™ vaccine adjuvanting platform and product candidates for cancer therapy and infectious diseases. We invite you to learn more about our two therapeutic cancer vaccines in development, DPX-Survivac and DPX-0907, and the potential of our DepoVax platform to produce a strong, high quality and sustained immune response.
Immunovaccine's DepoVax™ vaccine adjuvanting platform works with a variety of antigens. DepoVax™ creates a unique depot that attracts antigen-presenting cells to the injection site to potentially generate a rapid and robust immune response. The DepoVax™ platform is chemically stable, flexible and can be scaled up commercially. We invite vaccine developers to learn more about our licensing opportunities through the “DepoVax Challenge”.
